11:46 AM EST, 11/18/2026 (MT Newswires) -- European stock markets closed lower in Wednesday trading as rising energy prices continued to drive inflation higher in the euro area and the European Union.
The Stoxx Europe dropped 1.1%, Germany's DAX lost 1.2%, the FTSE 100 shed 1.4%, France's CAC declined 0.9%, and the Swiss Market Index decreased 0.6%.
The euro area annual inflation rate was 4.0% in October, up from 3.8% in September, and 2.1% a year earlier, according to Eurostat, the statistical office of the EU. EU annual inflation was also 4.0% in October, up from 3.8% in September, and 2.5% a year earlier.
The lowest annual rates were in Sweden (0.6%), Czechia, and Denmark (2.1% each). The highest annual rates were in Romania (7.0%), Lithuania (6.1%) and Bulgaria (5.9%). Compared with September, annual inflation rose in 16 countries, fell in nine countries, and remained unchanged in two.
In corporate news, Deutsche Bank has cleared thousands of likely illicit transactions in Colombia, revealing significant gaps in monitoring at its local unit, the Financial Times reported Wednesday, citing internal documents from a 2020 review of the bank's operations known as Project Cali.
The documents showed that Deutsche Bank had only filed less than 10 suspicious activity reports in one year even after processing 20 billion euros ($21.93 billion) for Colombia's top banks, the news outlet said. The review eventually led Deutsche Bank to file at least 294 suspicious activity reports covering transactions linked to suspected drug trafficking, money laundering and sanctions, the report said.
The bank said the review led to specific corrective measures and a broader reassessment of financial-crime risks, and Germany's financial regulator BaFin granted the bank another extension last month to meet a deadline for improving its systems, the FT reported.
According to the Financial Times, the documents were leaked from inside the company and have been analyzed by more than 200 journalists worldwide.
Deutsche Bank did not immediately respond to MT Newswires' request for a comment.
Shares of Deutsche Bank fell 3.2% in Frankfurt.
GSK said late Tuesday the US Food and Drug Administration granted accelerated approval to Nelkarmi for adults with advanced ALK-positive lung cancer who have already been treated with an ALK inhibitor.
In a phase 1/2 trial, 49% of patients who received alectinib as their only prior treatment responded and 32% of those with two or more prior treatments responded, the drugmaker said.
Brain metastasis response rates were 55% in the alectinib-only group, and the most common side effects were liver toxicity, muscle pain, and constipation, with 5% of patients stopping the treatment, GSK said.
The approval came ahead of the FDA's Nov. 27 target date and follows breakthrough therapy and orphan drug designations, it said.
Shares of GSK decreased 0.4% in London.
Equinor said Wednesday that it has identified the scope of a cyberattack targeting certain IT systems, with no indication of data theft or impact on employees, partners or suppliers.
The company said production and operations remain unaffected and the incident is not a virus attack, posing no risk of spreading.
Equinor said it is working with national security authorities to neutralize the attack and restore affected systems, but the company added that it is too early to determine how long the recovery process will take.
Shares of the Norwegian petroleum refiner lost 1.4% in Oslo.
AstraZeneca and Tempus AI have extended their 2021 master services agreement through Dec. 31, 2031, with AstraZeneca committing to pay a total of $200 million in fees, Tempus AI said in a filing Wednesday.
The new financial commitment period will take effect Jan. 1 and extend the strategic collaborator benefits provided to AstraZeneca under the 2021 agreement, according to a filing with the US Securities and Exchange Commission.
AstraZeneca has committed to spend at least $32 million per year over the renewal period, with a potential one-year extension should there be a shortfall in spending, according to the filing. Tempus AI said AstraZeneca maintains the right to terminate the agreement at any time, but will still be required to complete the $200 million financial commitment.
Shares of the British pharmaceutical company dropped 1.3% in London.
Stellantis and Volkswagen are among the potential local partners China's Hongqi is evaluating as it plans to manufacture cars in Europe, Reuters reported Tuesday, citing a senior executive.
Hongqi, the luxury car brand of state-owned FAW Group, is prioritizing localization in Europe, FAW's international business chief Xiao Xiao was quoted as saying.
Volkswagen and FAW are not in discussions about European production, a Volkswagen spokesperson told Reuters.
Stellantis, Volkswagen and Hongqi did not immediately respond to MT Newswires' requests for comment.
Shares of Stellantis and Volkswagen were down 1.3% each in Paris and Frankfurt respectively.
Novo Nordisk and Nference have launched a collaboration to advance research in cardiometabolic diseases, including conditions such as obesity, diabetes, and cardiovascular disease, Nference said Wednesday.
The partnership will combine Novo's clinical trial data with Nference's AI technology and healthcare data network to assist in healthcare research and in identifying future research opportunities, Nference said.
Shares of the Danish pharmaceutical company closed 1.5% lower in Copenhagen.
Eni unit Plenitude has signed a four-year power purchase agreement with Italian food producer Orva to supply 4 gigawatt-hours of electricity annually, the companies said Wednesday.
The agreement covers a total of about 16 GWh of electricity and guarantees of origin tied to renewable output from Plenitude's Montalto di Castro agrivoltaic plant in Italy.
The supply contract will take effect Jan. 1, 2027, and cover about 40% of Orva's annual electricity needs, the companies said.
The contract will allow Orva to plan energy costs over the medium term, it said.
Shares of the Italian oil and gas company fell 1.8% in Milan.
Royal Philips said Wednesday it introduced Philips Skylight Device Manager, a cloud-based application that provides a centralized view of data across connected ultrasound systems.
The company also said it plans to expand Skylight Device Manager to include additional imaging modalities like diagnostic x-ray systems.
Shares of the Dutch healthcare tech conglomerate gained 0.1% in Amsterdam.
http://www.mtnewswires.com
Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.